Kai Hwang

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Kai Hwang sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed upper half by trial count

Kai Hwang: 2 sponsored US clinical trials, 1 recruiting.

Kai Hwang sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Attention Deficit Disorder With Hyperactivity (ADHD), with 1 trials.

Mid-pack sponsor footprint

Kai Hwang is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Kai Hwang pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Attention Deficit Disorder With Hyperactivity (ADHD) (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kai Hwang: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Kai Hwang sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Kai Hwang1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Kai Hwang sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kai Hwang sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Kai Hwang page

2 registered trials is a research-attention snapshot, not an endorsement of Kai Hwang or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kai Hwang pipeline card: 2 registered trials from official public datasets.Report a data error.